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Many risk factors for lung disease in cystic fibrosis (CF) display a seasonal pattern yet it is 
unclear whether this is reflected in seasonal fluctuations in lung function. 
Methods 
We conducted a longitudinal study using CF registries in Denmark and the UK. 485 
individuals with a median of 103 FEV1 measurements per person and 7622 individuals with a 
median of nine FEV1 measures per person were included from Denmark and the UK 
respectively. We estimated the effect of seasonality on percent predicted FEV1 trajectories 
using mixed effects models whilst adjusting for clinically important covariates. 
Results 
We found no significant cyclical seasonal variation in lung function in either country. The 
maximum variation in percent predicted FEV1 around the yearly average was estimated to 
be 0.1 percentage points (95%CI 0 to 0.21) and 0.14 percentage points (95%CI 0 to 0.29) in 
Denmark and the UK, respectively. When considering possible step-like changes between 
the four seasons, we found that lung function was higher in spring compared to winter in 
the UK (0.34 percentage points, 95%CI 0.1 to 0.59) though the difference was not of clinical 
significance.  
Conclusion 
In both the UK and Denmark there may be small seasonal changes in lung function but this 
effect is not of clinical importance. 
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 1. Introduction 
Seasonal patterns in respiratory outcomes in conditions such as asthma and COPD are well 
recognised in terms of lung function, admissions to hospital and deaths (1,2). Furthermore, 
theories about seasonal variations in cystic fibrosis (CF) morbidity are common, though they 
often rely more on shared observations and clinical hunches than hard evidence. For 
example in the early days of CF medicine a puzzling seasonal trend in CF mutations at birth 
was observed (3), but quickly debunked as a case of ascertainment bias (4). It is perhaps not 
surprising that theories on climate and seasonal variations are common in CF; weather is a 
popular topic, probably because it is a shared experience, ripe for pattern-finding (5,6). 
More importantly, many of the significant risk factors associated with CF pulmonary disease 
display seasonal variability. The most well-known examples are seasonal influenza 
outbreaks, which lead to increased mortality in the general population (7) and in CF 
populations, where rates of pulmonary exacerbations increase during epidemics (8). 
Likewise, acquisition of Pseudomonas aeruginosa has been shown to exhibit seasonal 
variation, such that US children with CF in temperate and continental climate zones have a 
higher incidence in summer months (9), with no difference among children in dry climate 
zones.  Conversely, an early Danish study showed more Pseudomonas acquisition in winter 
(10).  
In the context of a multitude of interacting risk and protective factors influencing CF 
outcomes over time, and given the inherent variability in lung function measures in people 
with CF (11), any seasonality effect on risk factors and clinical outcomes is difficult to isolate. 
Furthermore it is unclear whether seasonality affects lung function, the main clinical 
morbidity indicator in CF. We therefore developed a longitudinal model for evaluating lung 
function changes over time in people with CF, and applied it to two CF populations in 
Northern Europe. The aim of our study was to assess seasonal fluctuations in lung function 
at the population level. 
 
2. Methods 
2.1 Study Design, Setting, Data Sources and Participants 
We carried out longitudinal analyses of lung function in individuals with CF captured in the 
Danish and UK CF registers between 1974 and 2014 and between 1996 and 2015, 
respectively. Individuals born before 1969 were excluded to reduce the influence of survivor 
bias (11). Lung function measurements taken post-transplant or before the age of five were 
also excluded. 
In Denmark, individuals with CF were followed up monthly in one of the two CF centres in 
Copenhagen and Aarhus. Measurements were recorded in the Danish CF Patient Registry, 
which was established in 1974 but includes records going back to the 1960s and has an 
almost complete record of all individuals living with CF in Denmark from 1990 onwards 
when CF care was centralised. In the UK individuals with CF are seen in one of 50 specialist 
CF centres and it is recommended that the annual encounter data submitted to the Registry 
is from a clinic visit roughly 12 months after the previous entry and when the patient is 
clinically stable. . Records date back to the 1990s and are estimated to capture 99% of the 
current UK CF population (see (12) for more details). In both countries, the follow-up 
reviews include evaluation of clinical status, lung function, and microbiology of respiratory 
tract secretions.  
2.2 Outcome, exposure and covariates 
Our outcome of interest was lung function from age 5 as measured by percent of predicted 
forced expiratory volume in one second (%FEV1). Pulmonary function tests were performed 
at the monthly/annual review visits. Measurements were expressed as a percentage of 
predicted values for sex and height in Denmark (13,14), and as a percentage of predicted 
values for sex, age, height and ethnicity in the UK. (15) Our exposure of interest was the 
time of year of measurement. Two variables were created for this. One was a 4 level 
categorical variable for the season during which the review visit took place, where 
December, January, and February were coded as ‘winter’, March, April, and May as ‘spring’, 
June, July and August as ‘summer’ and September, October, November as ‘autumn’. Our 
other approach was to use the day of year that the visit date was recorded in the registry, 
where 1st January is day zero and 31st December is day 365/ 366.  
In both populations we adjusted for the following time-invariant covariates: age at 
diagnosis, birth cohort, pancreatic insufficiency (PI, coded as 0 or 1 according to whether PI 
was ever diagnosed), genotype (coded as the number of F508del alleles (0, 1 or 2)) and sex. 
We also adjusted for age and CF related diabetes (CFRD) as well as chronic pseudomonas as 
time varying covariates (the latter two coded as 0 or 1). In the UK we additionally included 
deprivation z-score based on the index of multiple deprivation (IMD), ethnicity (grouped as 
White, Black, North East Asian, South East Asian, Other/Mixed) and a binary indicator for 
diagnosis by new-born screening.  
2.3 Statistical Analysis 
We developed a longitudinal model for lung function in Denmark and in the UK using a 
previously published approach (11,16). In brief, we developed a linear model for the 
population average lung function, in which both the intercept at age 5 and the slope depend 
on the time-invariant covariates and the slope additionally depends on CFRD and chronic 
pseudomonas. The lung function measurements within an individual are correlated, but as 
the healthcare systems differ between countries, we cannot assume the underlying 
stochastic process to be the same in the Danish and UK CF populations and we therefore 
modelled the data from each country separately. Due to the different follow-up procedure, 
the short term-correlation that is captured in Denmark cannot be quantified in the UK. 
Therefore, we used different models for the longitudinally structured correlation; in 
Denmark we used an exponentially decaying function of time difference (11) whereas in the 
UK we used a random slope model (16). Both models included a random intercept to take 
into account the between individual heterogeneity in baseline lung function. See 
Supplementary Material for the model equation and further details.  
To assess whether there are seasonal fluctuations in lung function, we added the time of 
year as a time-varying covariate to the model using two different approaches. In the first 
approach we used a categorical variable with the levels ‘winter’, ‘spring’, ‘summer’ and 
‘autumn’ as an explanatory variable of lung function. We used ‘winter’ as the reference level 
as it may be plausible that lung function is lowest during this time. In the second approach, 
we modelled smooth changes in lung function according to season using a sine wave where 
the period is one year (365.25 days) and the amplitude and horizontal shift are model 
parameters to be estimated from the data (see Supplementary Material for further details).  
We fitted the model using maximum likelihood estimation (ML) and the R package nlme 
(17). Statistical significance of a seasonal effect was assessed with a likelihood ratio test. 
Confidence intervals for the categorical ‘season’ variable were constructed using the R 
function intervals.lme, which uses a normal approximation of the ML estimators for the 
average differences in lung function in spring, summer and autumn compared to winter. For 
the approach using the sine wave, confidence intervals for the amplitude and the phase 
shift were also based on a normal approximation (more details are given in the 
Supplementary Material). Only individuals with complete information on the baseline 
covariates were included in the analysis.  
2.4 Robustness test and additional analysis 
 As a robustness test, we repeated the analysis dropping measurements taken from 
individuals born before 1991 in the UK to reduce any remaining potential influence of 
survivor bias in this population. To assess whether the seasonal patterns differed between 
children and adults we re-fitted the models with the sine wave in both countries including 
an interaction term between the sine function and an indicator for < or ≥ 18 years of age. 
2.5 Ethical Considerations 
NHS research ethics approval (Huntingdon Research Ethics Committee 07/Q0104/2) was 
granted for the collection of data into the UK database. The Cystic Fibrosis Trust database 
committee approved the use of anonymised data in this study. In Denmark the study was 
approved by the Danish Data Protection Agency (file no. 2008-41-2682). 
2.6 Role of the funding source 
This work was funded by the UK Cystic Fibrosis Trust through the Strategic Research Centre 
“EpiNet: Harnessing data to improve lives”. DTR was also funded by the MRC on a Clinician 
Scientist Fellowship (MR/P008577/1). The funder was not involved in the study design, data 
collection, data analysis, data interpretation, or in the writing of the report. The 
corresponding author had full access to all the data in the study and final responsibility for 




485 individuals in the Danish CF Registry were born between 1969 and 2009 all of whom 
had at least one lung function measurement after the age of 5. Age at diagnosis was missing 
in 14 individuals who were thus excluded from the analysis.. The median follow-up time was 
12.6 years with a median of 104 FEV1 measures per patient. In the UK CF Registry 10,269 
individuals were born between 1969 and 2010; 9667 had lung function measurements after 
the age of 5 out of which 7586 had complete covariate data (see Supplementary Material 
for a comparison of the demographics). The median follow-up time in the UK study 
population was 10.4 years with a median of nine FEV1 measures. Table 1 gives the 
demographics of the study population stratified by birth cohort. Follow-up visits were 
approximately evenly distributed across the year in Denmark and increased slightly in 
frequency towards the end of the year in the UK (see Table 2). 
Table 1: Demographics of the study population by country and birth cohort. 






















n    97  110  144  113    7  471   790 1852 2546  2011 387 7586 
Sex=male (%)   51 
(52.6
)  
  57 
(51.8
)  
  66 
(45.8
)  
  52 
(46)  










































#F508del alleles  
 (%) 
            
0    0 ( 
0.0)  
   2 ( 
1.8)  
   0 ( 
0.0)  
   1 ( 
0.9)  
   0 (  
0.0) 
   3 ( 
0.6) 
   71 ( 
9.0)  
 146 ( 
7.9)  
 202 ( 
7.9)  
  175 
( 8.7)  
   43 
(11.1
) 
  637 
( 8.4) 
1    6 ( 
6.2)  
  10 ( 
9.1)  
   8 ( 
5.6)  
   5 ( 
4.4)  
   0 (  
0.0) 
  29 ( 
6.2) 
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Diagnosis by NBS 
(%) 
NA NA NA NA NA NA    12 ( 
1.5)  





  444 
(22.1
)  






Mean IMD z-score  
(sd) 



















insufficient  (%) 




































CFRD during study 
period (%) 
  37 
(38.1
)  
  33 
(30.0
)  
  27 
(18.8
)  
   1 ( 
0.9)  
0  
(  0.0)  
  98 
(20.8
) 









  271 
(13.5
)  





Chronic PA during 
study period (%) 
  71 
(73.2
)  
  52 
(47.3
)  
  37 
(25.7
)  
  10 ( 
8.8)  
0  
(  0.0)  
170 
(36.1
)   









  577 
(28.7
)  











































NBS: Newborn bloodspot screening 
IMD: Index of multiple deprivation where higher scores equate to higher deprivation 
CFRD: CF related diabetes 
PA: Pseudomonas Aeruginosa 
 
 
Table 2: Number of FEV1 measurements (%) taken in the four season and their unadjusted mean values across all 
individuals (standard deviation). 
Country winter spring summer autumn 

























































3.2 Seasonal effects on lung function 
In the Danish population the overall effect of seasonality on lung function was not 
significant at the 5% level in either the model with the categorical season variable or the 
model with the sine function. Parameter estimates, confidence intervals and likelihood-ratio 
test p-values are given in Table 3. Lung function was not found to differ significantly 
between spring, summer or autumn and winter. Using the sine wave to capture smoothly 
varying seasonal fluctuations, we estimated an amplitude of 0.1 percentage points (95%CI 0 
to 0.21). The horizontal shift was estimated to be 148.47 days (95%CI -182.32 to 182.61) . 
Thus lung function was estimated to peak on 28th  August and dip on the 27th  February. 
Confidence intervals for both dates covered the entire year. Amplitude and horizontal shift 
are however correlated; Figure 1 shows their joint 95% confidence region. Only for a 
horizontal shift greater than 63 days or less than -130 days, which equates to lung function 
peaking between June and October, was the upper 95% bound for the amplitude greater 
than 0.05 (see Supplementary Material for details). 
In the UK, the overall effect of seasonality on lung function was only marginally not 
significant at the 5% level. Lung function was estimated to be significantly higher in spring 
compared to winter (0.34 percentage points (95%CI 0.1 to 0.59)), whereas there was no 
significant difference between lung function in summer or autumn and winter. Using the 
sine function, we estimated an amplitude of 0.14 percentage points (95%CI 0 to 0.29). The 
horizontal shift was estimated to be 66.2 (95%CI -182.25 to 179.51). Thus lung function was 
estimated to peak on the 7th June and dip on the 6th December, with confidence intervals for 
both dates covering the entire year. However, the upper 95% confidence limit for the 
amplitude was greater than 0.05 only for horizontal shifts between -26 and 157 days, which 
equates to lung function peaking between March and September (see Figure 1). 
Figure 2 shows the modelled cyclical seasonal fluctuation in percent predicted FEV1 in both 
countries. 
 
Tables S2 and S3 in the Supplementary Material give all parameter estimates and 95% 
confidence intervals for the covariates included in the model; Tables S4 and S5 in the 
Supplementary Material give the estimated Variance-Covariance parameters. 
Table 3: Parameter estimates 95% confidence intervals for the seasonal effects on percent predicted FEV1 and p-values 
from the Likelihood ratio test. 
 
 
3.3 Robustness test and additional analysis 
Repeating the analysis in the UK only on individuals with CF born after 1991 reduced the 
point estimates, but the confidence intervals were compatible with the previously 
presented results. Details are given in the Supplementary Material.  
In the additional analysis, which included an interaction effect between the sine function 
and an indicator for < or ≥ 18 years of age, we did not find any significant differences in 
seasonal patterns in lung function between children and adults. See Supplementary 
Material for details.   
Parameters Denmark UK 





spring 0.01 (-0.15 to 
0.18) 
0.34 0.34 (0.1 to 
0.58) 
0.06 
summer 0.1(-0.07 to 
0.28) 
0.21 (-0.04 to 
0.45) 
autumn 0.13 (-0.03 to 
0.2) 
0.17 (-0.06 to 
0.39 ) 
Amplitude of sine wave (percentage 
points) 
0.1 (0, 0.21) 0.07 0.14 (0 to 0.29) 0.07 





We carried out a longitudinal analysis of lung function change over time in two national 
Northern European CF populations and found that there is no clinically important seasonal 
variation in lung function. 
Given the reported seasonal fluctuation of some risk factors for adverse CF outcomes, such 
as influenza epidemics and PA acquisition, the lack of any substantive seasonal variation in 
lung function is perhaps an unexpected finding. Rates of pulmonary exacerbations have 
been reported as being more frequent during influenza epidemics (8). Acquisition of 
Pseudomonas aeruginosa has also been shown to demonstrate seasonal variation, either 
with a higher incidence in summer (9), or in winter (10), depending on the geographical 
location.  
A clear seasonal variability in non-influenza respiratory viruses has also been observed in CF, 
but this season effect does not translate to pulmonary exacerbations (18). A study from the 
CF Foundation National Patient Registry showed that MRSA was more frequently acquired in 
autumn and winter, whereas A. xylosoxidans acquisition was lower in spring. For H. 
influenzae, winter and spring were associated with higher acquisition. No seasonal variation 
was observed for S. maltophilia acquisition (19). It is well established that there are higher 
mould counts in the outdoor environment in autumn and this has been suspected to lead to 
higher risks of pulmonary Aspergillus and ABPA (20), but other reports have found that even 
adequate climate conditions for Aspergillus are in themselves not ideal conditions for 
increased acquisition (21). Other environmental factors that show seasonal variability, but 
where influence on morbidity in CF is unclear, include ambient temperatures (22), air 
humidity and domestic water temperature (23). All of these might be expected to affect the 
prevalence or virulence of well-known CF pathogens, but clear evidence is lacking. The 
connection between season, pathogen acquisition and lung function in CF is thus clearly not 
straightforward.  
In addition vitamin-D levels are also known to fluctuate with sun exposure during the 
calendar year. Such fluctuations might be expected to be mirrored in a hard outcome such 
as lung function, but this link has also turned out not to be direct (24). Dehydration during 
warm weeks is a risk factor for obstipation, but not for lung function (25). Altered clinic 
opening hours during vacation periods, patient travel patterns during the calendar year, and 
respiratory outbreaks during seasonal CF community events (26,27) could all effect groups 
of patients, but the effect on a population level is uncertain.  
 
There are a number of potential explanations for the lack of seasonal variation in lung 
function in our study.  Firstly, the size of any seasonal fluctuation in risk factors and 
subsequent impact on lung function may have previously been overestimated, or other, 
differently distributed and more dominant effects may lessen their impact. Secondly, it is 
possible that CF maintenance therapy and exacerbation management in the UK and 
Denmark is able to mitigate any negative effects of the winter season. A recent study in the 
US found that patients in the CFF Registry had a higher lung function in January compared to 
July. Similar to our findings, the difference at the population level was small and clinically 
insignificant at an average of about 1.2 %FEV1 (28). We found lung function to be higher in 
spring than in winter in the UK but did not find a statistically significant difference between 
winter and summer. The US study also showed that the effect of annual average 
temperatures on lung function dominated over seasonal fluctuations. The differences in 
climate between northern Europe and the US may therefore go some way in explaining any 
differences in findings. 
4.1 Strengths and weaknesses 
A strength of this analysis is that we analysed two well-characterised population-level CF 
registry datasets, with consistent findings across the two analyses, using up to date 
statistical approaches appropriate to the differing data collection pattern in the two 
datasets. The Danish dataset had monthly visit frequency of examinations facilitating 
precise estimation of change within individuals over time. By contrast, the UK dataset 
contains many more individuals but has less frequent follow-up throughout the year, 
allowing more precise estimation of the cross-sectional effect of seasonality. A limitation of 
our analysis is that we did not have data on the precise date of onset of PA or other 
respiratory pathogens in either dataset, and thus were not able to assess if there was 
seasonal variation in these risk factors. Similarly, we did not have data on potential changes 
in CF management throughout the year, making it impossible to determine whether 
responses from clinical staff mitigate any potentially negative effects of seasonal changes in 
pathogens and environmental factors on lung function.  
5. Conclusion 
Our findings from the analysis of national CF registry populations in Denmark and the UK 
suggest that there is no clinically significant seasonality effect on lung function.   
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Figure 2: Estimated seasonal fluctuation in percent predicted FEV1. The shaded regions are the 95% confidence regions. 0 
on the x-axis represents the 1st January. 
 
